MX2014004159A - Variantes de factor de crecimiento de fibroblasto 21. - Google Patents
Variantes de factor de crecimiento de fibroblasto 21.Info
- Publication number
- MX2014004159A MX2014004159A MX2014004159A MX2014004159A MX2014004159A MX 2014004159 A MX2014004159 A MX 2014004159A MX 2014004159 A MX2014004159 A MX 2014004159A MX 2014004159 A MX2014004159 A MX 2014004159A MX 2014004159 A MX2014004159 A MX 2014004159A
- Authority
- MX
- Mexico
- Prior art keywords
- variants
- growth factor
- fibroblast growth
- fgf21
- dyslipidemia
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542906P | 2011-10-04 | 2011-10-04 | |
| PCT/US2012/057053 WO2013052311A1 (en) | 2011-10-04 | 2012-09-25 | Fibroblast growth factor 21 variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014004159A true MX2014004159A (es) | 2015-02-12 |
Family
ID=46964112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004159A MX2014004159A (es) | 2011-10-04 | 2012-09-25 | Variantes de factor de crecimiento de fibroblasto 21. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8541369B2 (enExample) |
| EP (1) | EP2763689B1 (enExample) |
| JP (1) | JP6060167B2 (enExample) |
| KR (1) | KR20140059271A (enExample) |
| CN (1) | CN103906530B (enExample) |
| AP (1) | AP2014007532A0 (enExample) |
| AR (1) | AR087973A1 (enExample) |
| AU (1) | AU2012318956A1 (enExample) |
| BR (1) | BR112014007532A2 (enExample) |
| CA (1) | CA2843520A1 (enExample) |
| CL (1) | CL2014000801A1 (enExample) |
| CO (1) | CO6910165A2 (enExample) |
| CR (1) | CR20140142A (enExample) |
| DO (1) | DOP2014000050A (enExample) |
| EA (1) | EA201490521A1 (enExample) |
| EC (1) | ECSP14013285A (enExample) |
| ES (1) | ES2548214T3 (enExample) |
| IL (1) | IL230754A0 (enExample) |
| IN (1) | IN2014CN00782A (enExample) |
| MA (1) | MA35458B1 (enExample) |
| MX (1) | MX2014004159A (enExample) |
| PE (1) | PE20142044A1 (enExample) |
| PH (1) | PH12014500740A1 (enExample) |
| SG (1) | SG11201401792UA (enExample) |
| TN (1) | TN2014000096A1 (enExample) |
| TW (1) | TWI461435B (enExample) |
| WO (1) | WO2013052311A1 (enExample) |
| ZA (1) | ZA201400882B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| CA2869320A1 (en) * | 2012-05-15 | 2013-11-21 | Eli Lilly And Company | Therapeutic uses of fibroblast growth factor 21 variant proteins to increase bone formation or depositions |
| CN104364261B (zh) | 2012-06-11 | 2017-04-05 | 伊莱利利公司 | 成纤维细胞生长因子21变体 |
| TWI513705B (zh) * | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease |
| SG11201602870YA (en) | 2013-10-28 | 2016-05-30 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| EP3125921B1 (en) * | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| BR112017008157A2 (pt) | 2014-10-24 | 2017-12-19 | Bristol Myers Squibb Co | polipeptídeos de fgf-21 modificados e usos dos mesmos |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| WO2017220706A1 (en) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN106432509B (zh) * | 2016-09-13 | 2019-05-21 | 河南师范大学 | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 |
| CN106397607A (zh) * | 2016-09-13 | 2017-02-15 | 河南师范大学 | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 |
| CN106220724B (zh) * | 2016-09-13 | 2019-10-11 | 河南师范大学 | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 |
| ES3014984T3 (en) | 2017-03-14 | 2025-04-28 | Sunshine Lake Pharma Co Ltd | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| EP3678686A1 (en) | 2017-09-08 | 2020-07-15 | Bristol-Myers Squibb Company | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| CN111601613A (zh) | 2017-12-22 | 2020-08-28 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| US11679143B2 (en) | 2018-02-08 | 2023-06-20 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| AU2019297327A1 (en) | 2018-07-03 | 2021-02-18 | Bristol-Myers Squibb Company | FGF21 formulations |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| EP3935075A4 (en) | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | POLYPEPTIDE MOLECULE AND APPLICATION THEREOF |
| CN114853908B (zh) | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| KR20220125289A (ko) | 2020-01-08 | 2022-09-14 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf-21 접합체 제제 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| KR20240034235A (ko) | 2021-07-14 | 2024-03-13 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 대사 장애를 위한 융합 폴리펩타이드 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| DK1789442T3 (da) * | 2004-09-02 | 2009-11-16 | Lilly Co Eli | Muteiner af fibroblastvækstfaktor 21 |
| KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| MX2010013333A (es) * | 2008-06-04 | 2011-04-05 | Amgen Inc | Mutantes fgf21 y usos de los mismos. |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| TWI560197B (en) | 2009-05-05 | 2016-12-01 | Amgen Inc | Fgf21 mutants and uses thereof |
-
2012
- 2012-09-20 AR ARP120103466A patent/AR087973A1/es unknown
- 2012-09-21 TW TW101134800A patent/TWI461435B/zh not_active IP Right Cessation
- 2012-09-25 MX MX2014004159A patent/MX2014004159A/es unknown
- 2012-09-25 EP EP12766847.3A patent/EP2763689B1/en active Active
- 2012-09-25 CN CN201280048530.2A patent/CN103906530B/zh not_active Expired - Fee Related
- 2012-09-25 CA CA2843520A patent/CA2843520A1/en not_active Abandoned
- 2012-09-25 EA EA201490521A patent/EA201490521A1/ru unknown
- 2012-09-25 PH PH1/2014/500740A patent/PH12014500740A1/en unknown
- 2012-09-25 IN IN782CHN2014 patent/IN2014CN00782A/en unknown
- 2012-09-25 AU AU2012318956A patent/AU2012318956A1/en not_active Abandoned
- 2012-09-25 BR BR112014007532A patent/BR112014007532A2/pt not_active IP Right Cessation
- 2012-09-25 US US13/626,308 patent/US8541369B2/en active Active
- 2012-09-25 PE PE2014000472A patent/PE20142044A1/es not_active Application Discontinuation
- 2012-09-25 SG SG11201401792UA patent/SG11201401792UA/en unknown
- 2012-09-25 ES ES12766847.3T patent/ES2548214T3/es active Active
- 2012-09-25 WO PCT/US2012/057053 patent/WO2013052311A1/en not_active Ceased
- 2012-09-25 KR KR1020147008644A patent/KR20140059271A/ko not_active Withdrawn
- 2012-09-25 AP AP2014007532A patent/AP2014007532A0/xx unknown
- 2012-09-25 JP JP2014534596A patent/JP6060167B2/ja active Active
-
2013
- 2013-08-13 US US13/965,243 patent/US8883726B2/en active Active
-
2014
- 2014-01-30 IL IL230754A patent/IL230754A0/en unknown
- 2014-02-05 ZA ZA2014/00882A patent/ZA201400882B/en unknown
- 2014-03-06 DO DO2014000050A patent/DOP2014000050A/es unknown
- 2014-03-06 TN TNP2014000096A patent/TN2014000096A1/en unknown
- 2014-03-17 CO CO14057034A patent/CO6910165A2/es unknown
- 2014-03-27 MA MA36861A patent/MA35458B1/fr unknown
- 2014-03-27 CR CR20140142A patent/CR20140142A/es unknown
- 2014-04-02 CL CL2014000801A patent/CL2014000801A1/es unknown
- 2014-04-04 EC ECSP14013285 patent/ECSP14013285A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000096A1 (en) | Fibroblast growth factor 21 variants | |
| MX2014015258A (es) | Variantes del factor 21 de crecimiento de fibroblasto. | |
| PH12014502766A1 (en) | Fibroblast growth factor 21 proteins | |
| TN2015000053A1 (en) | Fusion proteins for treating a metabolic syndrome | |
| MX2013005639A (es) | Metodos para el tratamiento de transtornos asociados con fgf21. | |
| TN2011000414A1 (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof | |
| UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
| IN2014DN09805A (enExample) | ||
| PH12013501686A1 (en) | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | |
| IN2014DN09804A (enExample) | ||
| IN2014KN02830A (enExample) | ||
| PH12014502537A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
| TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| IN2014DN09297A (enExample) | ||
| MX2011008857A (es) | Derivados de oxiindol con actividad agonistica del receptor de motilina. | |
| MX2012004282A (es) | Composiciones farmaceuticas. | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders | |
| MY171941A (en) | Pharmaceutical compositions |